Clinical Value of Autoantibody Prognostic Markers in Tumor Immune Checkpoint
Inhibitor Therapy.
10.3779/j.issn.1009-3419.2022.101.28
- Author:
Liyuan DAI
1
;
Xiaohong HAN
2
Author Information
1. Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,
Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China.
2. Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
- Publication Type:Review
- Keywords:
Autoantibody;
Immune checkpoint therapy;
IrAE;
Prognostic marker
- MeSH:
Humans;
Immune Checkpoint Inhibitors;
Immunotherapy/adverse effects*;
Lung Neoplasms/etiology*;
Neoplasms/drug therapy*;
Prognosis
- From:
Chinese Journal of Lung Cancer
2022;25(7):534-540
- CountryChina
- Language:Chinese
-
Abstract:
Serum autoantibody markers have the advantages of easy specimen acquisition, simple detection technology and dynamic real-time monitoring. With the wide application of immune checkpoint inhibitors in the treatment of malignant tumors, autoantibody markers in predicting tumor immune checkpoint inhibitors efficacy and forecasting irAEs (immune related adverse events) show good prediction of potential. This review mainly focused on the progress of autoantibody markers in the prediction of therapeutic effect and the monitoring of irAE in tumor immunotherapy.
.
